Trials / Completed
CompletedNCT05127837
CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies
Development of an Artificial Intelligence- Informed Digital Tool to Help Clinicians Practice Cognitive Behavioral Therapy for Psychosis (CBTp)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 601 (actual)
- Sponsor
- University of Washington · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this grant is to develop and evaluate an Artificial Intelligence-based clinical training tool--CBTpro--to support high-quality skills training in CBT for psychosis (CBTp). CBTpro will provide a rapid means of scaling and sustaining high-quality CBTp in routine care settings across the US.
Detailed description
This fast-track Small Business Technology Transfer (STTR) grant is a partnership between the University of Washington and private company LYSSN that includes the development and iterative testing of CBTpro, a Computerized Clinician Support Tool designed to teach behavioral health providers and students Cognitive Behavioral Therapy for psychosis (CBTp). CBTpro uses natural language processing to provide automated speech-to-text and machine learning to score trainee's responses to simulated patients with psychosis. Once technical reliability of the tool is achieved through iterative modifications based on usability and field trials, a randomized control trial will be conducted to assess CBTpro training vs. training as usual with N=100 providers / N=300 clients on clinician skills and client outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | CBTpro | CBTpro is a novel spoken language technology tool to support high-quality skills training in CBT for psychosis. |
Timeline
- Start date
- 2022-06-28
- Primary completion
- 2024-12-09
- Completion
- 2024-12-09
- First posted
- 2021-11-19
- Last updated
- 2026-02-27
- Results posted
- 2026-02-27
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05127837. Inclusion in this directory is not an endorsement.